Literature DB >> 2390061

Re-formation of disulphide bonds in reduced antithrombin III.

X J Sun1, J Y Chang.   

Abstract

Human antithrombin III (AT-III) contains three disulphide linkages (Cys-8-Cys-128, Cys-21-Cys-95 and Cys-247-Cys-430), and two of them (Cys-8-Cys-128 and Cys-21-Cys-95) are situated near the heparin-binding domain of the inhibitor. We demonstrate in this paper that: (i) partially reduced AT-III (with Cys-8-Cys-128 and Cys-21-Cys-95 quantitatively reduced) could be re-oxidized in air to regain 70-80% of its heparin cofactor activity and thrombin-inhibitory activity; (ii) completely reduced AT-III was re-oxidized under similar conditions and recovered 30-35% of it biological activities. Structural analysis of refolded AT-IIIs indicates that restorations of their disulphide contents and conformations (evaluated by chemical modification) are congruent with recoveries of their biological activities.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2390061      PMCID: PMC1131639          DOI: 10.1042/bj2690665

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  26 in total

1.  Evidence for a heparin-induced conformational change on antithrombin III.

Authors:  G B Villaneuva; I Danishefsky
Journal:  Biochem Biophys Res Commun       Date:  1977-01-24       Impact factor: 3.575

2.  High-sensitivity sequencing with a gas-phase sequenator.

Authors:  M W Hunkapiller; R M Hewick; W J Dreyer; L E Hood
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

3.  Binding of low-affinity and high-affinity heparin to antithrombin. Ultraviolet difference spectroscopy and circular dichroism studies.

Authors:  B Nordenman; I Björk
Journal:  Biochemistry       Date:  1978-08-08       Impact factor: 3.162

4.  The site in human antithrombin for functional proteolytic cleavage by human thrombin.

Authors:  I Björk; A Danielsson; J W Fenton
Journal:  FEBS Lett       Date:  1981-04-20       Impact factor: 4.124

5.  The heparin and pentosan polysulfate binding sites of human antithrombin overlap but are not identical.

Authors:  X J Sun; J Y Chang
Journal:  Eur J Biochem       Date:  1989-10-20

6.  Isolation and characterization of antithrombin III from human, porcine and rabbit plasma, and rat serum.

Authors:  T Koide
Journal:  J Biochem       Date:  1979-12       Impact factor: 3.387

7.  A disulfide bond in antithrombin is required for heparin-accelerated thrombin inactivation.

Authors:  M O Longas; W S Ferguson; T H Finlay
Journal:  J Biol Chem       Date:  1980-04-25       Impact factor: 5.157

8.  Binding of high affinity heparin to antithrombin III. Stopped flow kinetic studies of the binding interaction.

Authors:  S T Olson; K R Srinivasan; I Björk; J D Shore
Journal:  J Biol Chem       Date:  1981-11-10       Impact factor: 5.157

9.  Evidence by chemical modification for the involvement of one or more tryptophanyl residues of bovine antithrombin in the binding of high-affinity heparin.

Authors:  I Björk; K Nordling
Journal:  Eur J Biochem       Date:  1979-12-17

10.  The size and shape of human and bovine antithrombin III.

Authors:  B Nordenman; C Nyström; I Björk
Journal:  Eur J Biochem       Date:  1977-08-15
View more
  3 in total

1.  The N-terminal domain of antithrombin-III is essential for heparin binding and complex-formation with, but not cleavage by, alpha-thrombin.

Authors:  R C Austin; W P Sheffield; R A Rachubinski; M A Blajchman
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

2.  Cloning of the full-length cDNA of porcine antithrombin III and comparison with its human homolog.

Authors:  Younan Chen; Weidong Tan; Shengfang Qin; Jie Zhang; Hong Bu; Youping Li; Yanrong Lu; Jingqiu Cheng
Journal:  Comp Med       Date:  2009-08       Impact factor: 0.982

3.  Cellular folding pathway of a metastable serpin.

Authors:  Kshama Chandrasekhar; Haiping Ke; Ning Wang; Theresa Goodwin; Lila M Gierasch; Anne Gershenson; Daniel N Hebert
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-24       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.